Intraperitoneal immunotherapy of peritoneal carcinomatosis

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 2, 1998, Pages 121-140

  Freedman, Ralph S ^a   Lenzi, Renato ^a   Kudelka, Andrzej P ^a   Lawrence, David D ^a   Rosenblum, Michael ^a   Platsoucas, Chris D ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catheters; Gene modified and peptide vaccines; Intraperitoneal immunotherapy and tumor immunology; Peritoneal cavity; Radioimmunoconjugates; Recombinant cytokines and cellular therapies

Indexed keywords

CANCER VACCINE; CISPLATIN; INTERLEUKIN 12; MITOXANTRONE; MONOCLONAL ANTIBODY; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ABDOMINAL PAIN; ADOPTIVE IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; FLU LIKE SYNDROME; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; INTESTINE PERFORATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MORBIDITY; MORTALITY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; VOMITING;

CARCINOMA; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; PERITONEAL NEOPLASMS;

EID: 0031847331     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Russell AH, Pelton J, Reheis CE, Adenocarcinoma of the colon: an autopsy study with implications for new therapeutic strategies. Cancer (1985) 14: 46-51.
2. Welch JP, Donaldson GA, The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg (1979) 189: 496-502.
3. Bruckner H, Stablein D, Sites of treatment failure: gastrointestinal tumor study group analysis of gastric, pancreatic and colorectal trials. Cancer Treat Symp (1983) 2: 199-210.
4. Juhl H, Stritzel M, Wroblewski A et al, Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer (1994) 57: 330-5.
5. Landry J, Tepper J, Wood W et al, Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys (1990) 19: 1357-62.
6. DuPont JBJ, Lee JE, Burton GR, Cohn IJ, Adenocarcinoma of the stomach: review of 1497 cases. Cancer (1978) 41: 941-7.
7. Yonemura Y, Takashi F, Nishimura G, Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery (1996) 119: 437-44.
8. Hagiwara A, Takahashi T, Kojima O, Prophylaxis with carbonadsorbed mitomycin C against peritoneal recurrence of gastric cancer. Lancet (1992) 339: 629-31.
9. Johnstone PA, Sindelar WF, Patterns of disease recurrence following definitive therapy of adenocarcinoma of the pancreas using surgery and adjuvant radiotherapy: correlations of a clinical mal. Int J Radiat Oncol Biol Phys (1993) 27: 831-4.
10. McGuire WP, Hoskins WJ, Brady MF, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage HI and stage IV ovarian cancer. N Engl J Med (1996) 334: 1-6.
11. Dedrick RL, Meyers CE, Bungay PM, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 62: 2-11.
12. Alberts DS, Liu PY, Hannigan EV et al, Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage ITI ovarian cancer. N Engl J Med (1996) 335: 1950-5.
13. Dednck RL, Flessner MF, Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst (1997) 89: 480-7.
14. Almadrones L, Yerys C, Problems associated with the administration of intraperitoneal therapy using the port-a-cath system. Oncol Nurs Forum (1990) 17: 75-80.
15. Kirk IR, Carrasco CH, Lawrence DD et al, Intraperitoneal catheters: percutaneous placement with fluoroscopic guidance. J Vase Interv Radiol (1987) 4: 299-304.
16. Platsoucas CD, Autologous tumor-specific T cells in malignant melanoma. Cancer Metastasis Rev (1991) 10: 151-76.
17. Lenschow DJ, Walunas TL, Bluestone JA, CD2S/B7 system of T cell costimulation. Annu Rev Immunol (1996) 14: 233-58.
18. + T cells by B7-transfected melanoma cells. Science (1993) 259: 368-70.
19. Nagata S, Fas and fas ligand: a death factor and its receptor. Adv Immunol (1994) 57: 129-44.
20. Mossman TR, Cherwinski H, Bond MW et al, Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136: 2348-57.
21. Romagnani S, Induction of TH1 and TH2 responses: a key role for the 'natural' immune response. Immunol Today (1992) 13: 379-81.
22. Paul WE, Seder RA, Lymphocyte responses and cytokines. Cell (1994) 76: 241-51.
23. Matsuda M, Salazar F, Petersson M, Interleukin-10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 180: 2371-6.
24. Freedman RS, Tomasovic B, Templin S et al, Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Meth (1994) 167: 145-60.
25. - cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res (1998) 4: 799-809.
26. Freedman RS, Platsoucas CD, Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. In: Cancer Treatment and Research, Vol 82 (ed PH Sugarbaker) 115-46. Kluwer, Boston, 1996.
27. Ioannides CG, Platsoucas CD, Rashed S et al, Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res (1991) 51: 4257-65.
28. Ioannides CG, Freedman RS, Platsoucas CD, Kim Y-P, Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol (1991) 146: 1700-7.
29. Freedman RS, Ioannides CF, Mathioudakis G, Platsoucas CD, Novel immunologic strategies for the treatment of ovarian carcinoma based on cell surface recognition. Am J Obstet Gynecol (1992) 167: 1470-8.
30. Itoh K, Platsoucas CD, Balch CM, Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. J Exp Med (1988) 168: 1419-41.
31. Freedman RS, Wharton JT, Rutledge FN, Sinkovics JG, Transfer factor and possible applications in gynecology. Am J Obstet Gynecol (1978) 130: 572-84.
32. Nanno M, Seki H, Mathioudakis G et al, Gamma/delta T cell antigen receptors expressed on tumor-infiltrating lymphocytes. Eur J Immunol (1992) 22: 679-87.
33. Salmeron MA, Monta T, Seki H et al, Lymphokine production by human melanoma tumor-infiltrating lymphocytes. Cancer Immunol Immunother (1992) 35: 211-17.
34. Freedman RS, Edwards CL, Kavanagh JJ et al, Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low dose recombinant interleukin-2: a pilot trial. J Immunother (1994) 16: 198-210.
35. Peoples GE, Goedegebuure PS, Andrews JVR et al, HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol (1993) 151: 5481-91.
36. Ioannides CG, Freedman RS, Platsoucas CD, OKT4 monoclonal antibody-induced activation of an autoreactive T cell clone Cell Immunol (1989) 123: 244-52.
37. Kooi S, Freedman RS, Rodriquez-Villanueva J, Platsoucas CD, Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes (TIL) from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res (1993) 12: 429-37.
38. Dadmarz RD, Ordoubadi A, Mixon A et al, Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am (1996) 2: 263-72.
39. Nash MA, Edwards CL, Kavanagh JJ et al, Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumor specimens, peritoneal exudate cells containing tumor, TIL-derived T-cell lines and established tumor cell lines. Clin Exp Immunol (1998) in press.
40. Van der Bruggen P, Traversari C, Chomez P et al, A gene encoding an antigen recognized by cytolytic T cells on a human melanoma. Science (1991) 254: 1643-7.
41. Brichard V, Van Pel A, Wolfel T et al, The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 178: 489-95.
42. Bakker ABH, Schreurs MWJ, de Boer AJ et al, Melanocyte lineagespecific antigen gp 100 is recognized by melanoma-derived tumor infiltrating lymphocytes. J Exp Med (1994) 179. 1005-9.
43. Kawakami Y, Ehyahu S, Sakaguchi K et al, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 180: 347-52.
44. Coulie PG, Brichard V, Van Pel A et al, A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 180: 35-42
45. Boel P, Wildmann C, Sensi ML et al, BAGE: a new gene encoding an antigen recognized on human melanoma cytolytic T lymphocytes. Immunity (1994) 2: 167-75.
46. Van den Eynde B, Peeters O, De Backer O et al, A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 182: 689-98.
47. Wolfel T, Herr W, Coulie P et al, Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer (1993) 54: 636-44.
48. Ruzzo V, Dalerba P, Ricci A et al, MAGE, BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas. Int J Cancer (1996) 67: 457-60.
49. Fisk B, Blevins TL, Wharton JT, Ioannides CG, Identification of an immunodominant peptide of the HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med (1995) 181: 2100-17.
50. Linehan DC, Goedegebuure PS, Peoples GE et al, Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol (1995) 155: 4486-91.
51. Tandon AK, Clark GM, Chamness GC et al, HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 7: 1120-8.
52. Allred DC, Clark GM, Gandon AK et al, HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 10: 599-605.
53. Slamon DJ, Godolphin W, Jones LA et al, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244: 707-12.
54. Imanishi T, Akaza T, Kimura A et al, Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Proceedings of 11th International Histocompatibihty Workshop and Conference, Yokohama-shi, Japan, 1991 (ed K Tsuji, M Aizawa, T Sasazuki). Oxford University Press, 1992.
55. Yasoshima T, Sato N, Hirata K, Kikuchi K, The mechanism of human autologous gastric signet ring cell tumor rejection by cytotoxic T lymphocytes in the possible context of HLA-A3 molecule. Cancer (1995) 75: 1484-9.
56. Kumar A, Farace F, Gaudin C, Triebel F, Clonal T cell expansion induced by interleukin-2 therapy in blood and tumors. J Clin Invest (1996) 97: 1219-26.
57. Tsang KY, Zaremba S, Nieroda CA et al, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 87: 982-90.
58. McLaughlin JP, Schlom J, Kantor JA, Greiner JW, Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res (1996) 56: 2361-7.
59. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognized an epitope present on the protein core of mucin molecule preferentially expressed by malignant cells. Cancer Res (1991) 51: 2908-16.
60. Jerome KR, Bu D, Finn OJ, Expression of tumor-associated epitopes on Epstein-Barr virus-immortalized B-cells and Burkitt's lymphomas transfected with epithelial mucin complementary DNA. Cancer Res (1992) 52: 5985-90.
61. Jerome KR, Domenech N, Finn OJ, Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol (1993) 151: 1654-62.
62. Disis MD, Byrd DR, McCahill L et al, CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res (1995) 55: 2984-7.
63. Végh Z, Wang P, Vánky F, Klein E, Selective downregulated expression of major histocompatibility complex class I alleles in human solid rumors. Cancer Res (1993) 53. 2416-20.
64. Vánky F, Hising C, Sjöwall K et al, Interferon-γ and tumor necrosis factor-α treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes. J Interferon Cytokine Res (1996) 16: 201-7.
65. Rivoltini L, Barracchini KC, Viggiano V et al, Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes, Cancer Res (1995) 55: 3249-57.
66. Yang Y, Nunes FA, Brencsi K et al, Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA (1994) 91: 4407-11.
67. Kooi S, Zhang H-Z, Patenia R et al, HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol (1996) 174: 116-28.
68. Freedman RS, Nash MA, Zhang HZ et al, Intraperitoneal (IP) injection of rIFN-γ and rIL-2 modulate expression of HLA class I and II and TGFβ2 on tumor cells from epithelial ovarian carcinoma (EOC) patients (pts). In: Proceedings American Association for Cancer Research, 1996: A3334.
69. Greiner JW, Guadagni F, Goldstein D et al, Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol (1992) 10: 735-46.
70. de Waal MR, Haanen J, Spits H, Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med (1991) 174: 915-24.
71. Kasid A, Bell GI, Director EP, Effects of transforming growth factor-β on human lymphokine activated killer cell procedures. J Immunol (1988) 141: 690-8.
72. Donnet-Hughes A, Schriffin EJ, Huggett AC, Expression of MHC antigens by intestinal epithelial cells. Effect of transforming growth factor-beta-2 (TGF-β2). Clin Exp Immunol (1995) 99: 240-4.
73. Czarniecki CW, Chiu HH, Wong GHW et al, Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells. J Immunol (1988) 140: 4217-23.
74. Tsunawaki S, Sporn M, Ding A, Nathan C, Deactivation of macrophages by transforming growth factor-β. Nature (1988) 334: 260-4.
75. Bosco MC, Espinoza-Delgado I, Schwabe M, The gamma subunit of the interleukin-2 receptor is expressed in human monocytes and modulated by interleukin-2, interferon-γ, and transforming growth factor-β1. Blood (1994) 83. 3462-7.
76. Espinoza-Delgado I, Bosco MC, Musso T, Inhibitory cytokine circuits involving transforming growth factor-β, interferon-α, and interleukin-2 in human monocyte activation. Blood (1994) 83: 3332-8.
77. Weller M, Constam DB, Malipiero U, Fontana A, Transforming growth factor-β2 induces apoptosis of murine T cell clones without downregulating bcl-2 mRNA expression. Eur J Immunol (1994) 24: 1293-300.
78. Henriksen R, Gobl A, Wilander E et al, Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest (1995) 73: 213-20.
79. Gordinier M, Zhang HZ, Kidd L et al, Quantitative analysis of transforming growth factor-β (TGF-β) and HLA class I and II in epithelial ovarian cancer. In: Proceedings American Association for Cancer Research, New Orleans, 1998: A1033.
80. Fakhrai H, Dorigo O, Shawler DL et al, Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA (1996) 93: 2909-14.
81. Greenburg PD, Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol (1991) 49: 281-355.
82. Chernoff AE, Granowitz EV, Shapior L et al, A randomized, controlled trial of IL-10 in humans. J Immunol (1995) 154: 5492-9.
83. Bost KL, Biegligk SC, Jaffe BM, Lymphokine mRNA expression by transplantable murine B lymphocytic malignancies: tumor-derived IL-10 as a possible mechanism for modulating the antitumor response. J Immunol (1995) 154: 718-29.
84. Freedman R, Nash M, Edwards C et al, Cytokine transcripts of peritoneal exudate cells (PEC) and TIL-derived T-cell lines from patients with epithelial ovarian carcinoma (EOC) and established EOC tumor cell lines. In: Abstracts 9th International Congress of Immunology, San Francisco, 23-29 July 1995: A3974.
85. Loercher AE, Nash MA, Edwards CL et al, IL-10 producing monocytes in malignant ascites from ovarian cancer patients. In: Proceedings American Association for Cancer Research, New Orleans, 1998: A1032.
86. Milstein C, Monoclonal antibodies. Cancer (1992) 49: 1953-7.
87. Sears HF, Herlyn D, Steplewski Z, Koprowski H, Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Respir Med (1984) 3: 138-50.
88. Steplewski Z, Lubeck M, Koprowski H, Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science (1983) 221: 865-7.
89. Hakomori S, Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res (1989) 52: 257-331.
90. Zhang S, Walberg LA, Ogata S et al, Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res (1995) 55: 3364-8.
91. Ordonez NG, Freedman RS, Herlyn M, Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol (1987) 26: 1-10.
92. Galli-Stampino L, Meinjohanns E, Frische K et al, T-cell recognition of tumor-associated carbohydrates. the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res (1997) 57: 3214-22.
93. MacLean GD, Reddish M, Koganty RR et al, Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus detox adjuvant. Cancer Immunol Immunother (1993) 36: 215-22.
94. Adiuri S, Helling F, Ogata S et al, Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother (1995) 41: 185-92.
95. Freedman RS, Recent immunologic advances affecting the management of ovarian cancer. In: Clinical Obstetrics and Gynecology, Vol 28 (ed EJ Quillan, JT Wharton) 849-67. Harper and Row, Philadelphia, 1985
96. Freedman RS, Edwards CL, Bowen JM et al, Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol (1988) 29: 337-47.
97. Freedman RS, Kouttab NM, Bowen JM et al, Lymphokine activity in malignant effusion after intracavitary viral oncolysates. Lymphokine Res (1989) 8: 115-22.
98. Freedman RS, Edwards CL, Bowen JM et al, Regional clinical responses following intraperitoneal injection of allogeneic viral oncolysate in patients with epithelial ovarian carcinoma. In: Proceedings of 2nd European Congress in Gynaecological Endoscopy and New Surgical Techniques, Heidelberg, Germany (ed G Bastert, D Wallwiener, J Keckstein) 35-42. Monduzzi Editore, Bologna, 1993.
99. Lotzová E, Savary CA, Freedman RS, Bowen JM, Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract. Cancer Immunol Immunother (1984) 17: 124-9.
100. Savage HE, Rossen RD, Hersh EM et al, Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res (1986) 46: 2127-33.
101. Bcrck JS, Hacker NF, Lichtenstein A et al, Intraperitoneal recombinant α-interferon for 'salvage' immunotherapy in stage ITI epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer Res (1985) 45: 4447-53.
102. Willemse PHB, De Vries EGE, Mulder NH, Aalders JG, Bouma J, Sleijfer DT. Intraperitoneal human recombinant interferon alpha-2b in minimum residual ovarian cancer. Eur J Cancer (1990) 26: 353-8.
103. Nardi M, Cognetti F, Pollera CF, Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer. A phase II study. J Clin Oncol (1990) 8: 1036-41.
104. Berek JS, Welander C, Schink JC et al, A phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol (1991) 40: 237-43.
105. Markman M, Berek JS, Blessing JA et al, Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplarin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of IP cisplatin and recombinant α-interferon Gynecol Oncol (1992) 45: 3-8.
106. Frasci G, Tortoriello A, Facchini G et al, Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot study. Eur J Cancer (1994) 30: 946-50.
107. Formelli F, Rossi C, Sensi ML, Parmiani G, Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. Int J Cancer (1988) 42: 952-7.
108. Ferrandina G, Melichar B, Loercher A et al, Growth inhibitory effects of sodium-phenylacetate (NSC #3039) on ovarian carcinoma cells in vitro. Cancer Res (1997) 57: 4309-15.
109. Melichar B, Ferrandina G., Kudelka AP et al, Inhibition of protein isoprenylation and the antitumor activity of aromatic acid derivatives on ovarian tumor cell lines. In: Proceedings American Association for Cancer Research, San Diego, CA, 1997: A646.
110. Angiolillo AL, Sgadari C, Taub D et al, Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo, J Exp Med (1995) 182: 155-62.
111. Pujade-Lauraine E, Guastella JP, Colombo N et al, Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 14: 343-50.
112. D'Acquisto R, Markman M, Hakes T et al, A phase I trial of intraperitoneal recombinant gamma interferon in advanced ovarian carcinoma. J Clin Oncol (1988) 6: 685-9.
113. Lotze MT, Custer MC, Rosenberg SA, Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg (1986) 121: 1373-9.
114. Melioli G, Sertoli MR, Bruzzone M et al, A phase I study of recombinant interleukin-2 intraperitoneal infusion in patients with neoplastic ascites: toxic effects and immunologic results. Am J Clin Oncol (1991) 14: 231-7.
115. Edwards RP, Gooding W, Lembersky BC et al, Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion J Clin Oncol (1997) 15: 3399-407.
116. Chapman PB, Kolitz JE, Hakes TB et al, A phase I trial of intraperitoneal recombinant interleukin-2 in patients with ovarian carcinoma. Invest New Drugs (1988) 6: 179-88.
117. Stewart JA, Belinson JL, Moore AL et al, Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res (1990) 50: 6302-10.
118. Steis RG, Urba WJ, VanderMolen LA et al, Intraperitoneal lymphokine-activated killer cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity, J Clin Oncol (1990) 8: 1618-29.
119. Canevari S, Stoter G, Arienti F et al, Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody J Natl Cancer Inst (1995) 87: 1463-9.
120. Ozols RF, Vermorken JB, Chemotherapy of advanced ovarian cancer: current status and future directions. Semin Oncol (1997) 24(Suppl 2): S2-1-9.
121. Brunda MJ, Interleukin-12. J Leukoc Biol (1994) 55: 280-8.
122. Desai BB, Quinn PM, Wolitzky AG et al, Distribution and regulation of receptor expression. J Immunol (1992) 148: 3125-32.
123. Naume B, Johnson AC, Espevik T, Sundan A, Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. Eur J Immunol (1993) 23: 1831-8.
124. Gately MK, Desai BB, Wolitzky AG, Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol (1991) 147: 874-82.
125. Chan SH, Perussia B, Gupta JW, Induction of interferon-γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med (1991) 173: 869-79.
126. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R, Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol (1992) 143: 127-42.
127. H2 cells. Eur J Immunol (1993) 23: 1762-70.
128. Manetti R, Parronchi P, Giudizi G et al, Natural killer cell stimulatory factor interleukin-12 (IL-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med (1993) 177: 1199-204.
129. Jelinek DF, Baaten JK, Role of IL-12 in human B-lymphocyte proliferation and differentiation. J Immunol (1995) 154: 1606-13.
130. Gately MK, Warrier RR, Honasoge S, Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int Immunol (1994) 6: 157-67.
131. McKnight AJ, Zimmer GJ, Wolf SF, Effects of IL-12 on helper T cell-dependent immune response in vivo. J Immunol (1994) 152: 2172-9.
132. Soiffer RJ, Robertson MJ, Murray C, Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood (1993) 82: 2790-6.
133. Brunda MJ, Luistro L, Warrier RR, Antitumor and antimetastatic activity of mterleukin-12 against murine tumors. J Exp Med (1993) 178: 1223-30.
134. Nasatala CL, Edington HD, McKinney TG, Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. Immunology (1994) 153: 1697-709.
135. Sgadori C, Angiolillo AL, Tosato G, Inhibition of angiogenesis by interleukin-12 is mediated by the inierferon-inducible protein 10. Blood (1996) 87: 3877-80.
136. Voest EE, Kenyon BM, O'Reilly MS, Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst (1995) 87: 581-6.
137. Tannenbaum CS, Wicker N, Armstrong D et al, Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12 J Immunol (1996) 156: 693-9.
138. Rao JB, Chamberlain RS, Bronte V et al, IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol (1996) 156: 3357-65.
139. Vagliani M, Rodolfo M, Cavallo F et al, Interleukin-12 potentiates the curative effect of a vaccine based on interleukin-2-transduced tumor cells. Cancer Res (1996) 56: 467-70.
140. Epenetos AA, Snook D, Durbin H et al, Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res (1986) 46. 3183-91.
141. Vriesendorp HM, Quadri SM, Williams JR, Radioimmunoglobulin therapy. In: High-Dose Cancer Therapy (ed JO Armitage, K. Antman) 84-123. Williams & Wilkins, Baltimore, 1992.
142. Freedman RS, Ioannides CG, Tomasovic B, Development of a cell surface reacting human monoclonal antibody agent in ovarian carcinoma. Hybridoma (1991) 10: 21-33.
143. Vriesendorp HM, Quadri SM, Jaeckle KA et al, Proposal for translational analysis and development of clinical radiolabeled immunoglobulin therapy. Radiother Oncol (1996) 41: 151-61.
144. Borchardt PE, Radiolabeled human monoclonal IgM for intracompartmental cancer therapy. PhD Dissertation, Graduate School of Biomedical Sciences, University of Texas, 1997.
145. Epenetos AA, Munro AJ, Stewart S et al, Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol (1987) 5. 1890-9.
146. Meredith RF, Partridge EE, Alvarez RD et al, Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med (1996) 37: 1491-6.
147. 90Y labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med (1995) 9: 1545-51.
148. Riva P, Tison V, Arista A et al, Radioimmunotherapy of gastrointestinal cancer and glioblastomas. Int J Biol Markers (1993) 8: 192-7.
149. Finkler NJ, Muto MG, Kassis AI et al, Intraperitoneal radiolabeled OC 125 in patient with advanced ovarian cancer. Gynecol Oncol (1989) 34: 339-44.
150. Stewart JSW, Hird SV, Snook D et al, Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol (1990) 8: 1941-50.
151. 177Lu-CC49: a phase I-II study. Gynecol Oncol (1997) 65: 94-101.
152. Jacobs AJ, Fer M, Su FM et al, A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol (1993) 82: 586-93.
153. Maraveyas A, Snook D, Hird V et al, Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer (1994) 73: 1067-75.
154. 131I-CC49 and Interferon-γ. Dis Colon Rectum (1994) 37(Suppl): S100-5.
155. Markman M, Reichman B, Hakes T et al, Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol (1992) 10: 1479-84.